Today: 29 April 2026
Browse Category

ASX:IPH 6 December 2025

Australian Stock Market Weekly Wrap: ASX 200 Edges Higher Amid ASX Outage, Strong GDP and Rate-Hike Jitters (1–6 December 2025)

Australian Stock Market Weekly Wrap: ASX 200 Edges Higher Amid ASX Outage, Strong GDP and Rate-Hike Jitters (1–6 December 2025)

The S&P/ASX 200 ended the first week of December slightly higher at 8,634.6, recovering from a 0.6% drop after a major ASX outage on Monday. September-quarter GDP rose 2.1% year-on-year, fueling rate hike speculation. October inflation held at 3.8%. Lithium miners and data-centre operator NextDC outperformed.
6 December 2025
·····

Stock Market Today

  • Ceres Power Surges Past Rolls-Royce, Nvidia, BP in FTSE 250 Rally
    April 29, 2026, 9:27 AM EDT. Ceres Power (LSE:CWR) leads the FTSE 250 stock gains in 2026 with a staggering 176% rise year-to-date, far outpacing Rolls-Royce, Nvidia and BP. The clean energy tech firm, specializing in licensing advanced solid oxide fuel cell and hydrogen technology, posted a remarkable 933% gain over the last year. Despite declining revenues - £32.6 million in 2025 down from £51.9 million the previous year - and no expected profits in 2026 or 2027, investor enthusiasm is fueled by the AI-driven data center boom. Its recent collaboration with Centrica aims to deploy efficient on-site power solutions swiftly for AI hubs and logistics centers. This positions Ceres as a crucial 'picks and shovels' provider amid the AI energy surge. However, over five years, the stock remains down 55%, prompting debate on its current valuation.

Latest article

Visa Stock Jumps as Earnings Beat and $20 Billion Buyback Ease Spending Fears

Visa Stock Jumps as Earnings Beat and $20 Billion Buyback Ease Spending Fears

29 April 2026
Visa shares jumped 5% premarket Wednesday after the company beat quarterly profit estimates, raised its full-year outlook, and announced a $20 billion buyback. Adjusted net income rose to $6.3 billion, or $3.31 a share, topping forecasts. Payments volume climbed 9%, cross-border volume 12%. Visa cited resilient consumer spending but flagged Middle East tensions as a risk to travel flows.
Regeneron Earnings Beat, But Eylea Still Clouds REGN Stock

Regeneron Earnings Beat, But Eylea Still Clouds REGN Stock

29 April 2026
Regeneron Pharmaceuticals reported first-quarter revenue of $3.605 billion, up 19%, and adjusted earnings of $9.47 per share, both above analyst estimates. Dupixent sales rose 33% and Libtayo 54%, while total U.S. Eylea sales fell 10%. Shares dropped 1.1% premarket. The FDA delayed a decision on a second Eylea HD syringe manufacturer; Regeneron cut its 2026 gross-margin forecast due to repairs in Ireland.
Go toTop